This document discusses the diagnosis and management of nephrotic syndrome in pediatric patients. It notes key risk factors like male gender, onset at age 1 year, and persistent proteinuria. It recommends full dose corticosteroid treatment and addresses potential adverse effects. It also discusses lifestyle modifications, preventing infections, and controlling electrolyte imbalances as part of the patient's management. The prognosis section covers potential complications like end-stage renal disease and risks to quality of life if nephrotic syndrome is not well controlled.
This document discusses the diagnosis and management of nephrotic syndrome in pediatric patients. It notes key risk factors like male gender, onset at age 1 year, and persistent proteinuria. It recommends full dose corticosteroid treatment and addresses potential adverse effects. It also discusses lifestyle modifications, preventing infections, and controlling electrolyte imbalances as part of the patient's management. The prognosis section covers potential complications like end-stage renal disease and risks to quality of life if nephrotic syndrome is not well controlled.
This document discusses the diagnosis and management of nephrotic syndrome in pediatric patients. It notes key risk factors like male gender, onset at age 1 year, and persistent proteinuria. It recommends full dose corticosteroid treatment and addresses potential adverse effects. It also discusses lifestyle modifications, preventing infections, and controlling electrolyte imbalances as part of the patient's management. The prognosis section covers potential complications like end-stage renal disease and risks to quality of life if nephrotic syndrome is not well controlled.
Persistent proteinuria Kidney biopsy Cyclosphorine Adverse effect of corticosteroid: O
Age at onset 1 year + full dose of Cushingoid feature(OR 1.77)(LOE 2) P
Male gender corticosteroid Cataracts and gloucoma (LOE 1) Steroid T Diarrhea resistant Risk of infection (RR 1.66) (LOE 3) Life style dification I Fever nephrotic Metabolic syndrome (LOE 1) M syndrome Prevention and A controlled of Not achieve remission infection ESRD 30-40% L after prednison in full (LOE 3) G dose therapy for 4 weeks Adverse effect of dietetic R cycloposphamide Survival rate (LOE 3) O Acute Diarrhe ACE inhibitor Palpebral edema with Mild - 5 years 61% W Proteinuria 1000 mg/dL Dehydration Kidney survival rate T Albumin 20% Hypoalbuminemia 1,2 (LOE 3) H g/dL - 5 years 58% & IgM dengue positif Low quality of life (LOE 3) D Imbalance elektrolit Quo ad vitam : ad bonam E Inj Ca gluconas (hypocalcemia Quo ad sanam : ad bonam V WAZ -1,19 SD Quo ad fungsional : ad E HAZ -1,86 SD malam M BMI for age 0,07 SD Well nourished Pediatric L nutrition care O P STIMULATING – LOVING – CARING – INTEGRATED PSYCOSOCIAL SUPPORT M E N Risk factor & findings Diagnosis & Management Prognosis T compilication